Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

British heart charity gets medtech boost:

This article was originally published in Clinica

Executive Summary

The British Heart Foundation (BHF) has announced the signing of an agreement that will provide significant funding for cardiac equipment, research and training. Under the deal, the charity will receive an expected £215,000 in annual donations from Candis Club magazine. Over the next twelve months, the funding will be used to purchase eight defibrillators, at a total cost of £20,000 ($31,300), and promote the charity's research and training funding programmes. The BHF recently announced plans to part fund the purchase of portable ultrasound scanners, in a bid to boost early diagnosis of heart failure where full echocardiography is not needed. It also provided funding for 20 two-year echocardiography training posts. The BHF is the UK's largest independent funder of heart disease research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT068481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel